Oramed Pharmaceuticals (ORMP) Short Interest Ratio & Short Volume $2.14 +0.08 (+3.88%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.13 -0.01 (-0.47%) As of 08/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Oramed Pharmaceuticals Short Interest DataOramed Pharmaceuticals (ORMP) has a short interest of 403,800 shares, representing 1.20% of the float (the number of shares available for trading by the public). This marks a -0.12% decrease in short interest from the previous month. The short interest ratio (days to cover) is 5.5, indicating that it would take 5.5 days of the average trading volume of 69,192 shares to cover all short positions.Current Short Interest403,800 sharesPrevious Short Interest404,300 sharesChange Vs. Previous Month-0.12%Dollar Volume Sold Short$868.17 thousandShort Interest Ratio5.5 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares41,000,000 sharesShort Percent of Float1.20%Today's Trading Volume59,277 sharesAverage Trading Volume69,192 sharesToday's Volume Vs. Average86% Short Selling Oramed Pharmaceuticals? Sign up to receive the latest short interest report for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartORMP Short Interest Over TimeORMP Days to Cover Over TimeORMP Percentage of Float Shorted Over Time Oramed Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/2025403,800 shares $868.17 thousand -0.1%1.2%5.5 $2.15 7/15/2025404,300 shares $844.99 thousand -3.4%N/A5.8 $2.09 6/30/2025418,700 shares $942.08 thousand -11.9%1.2%5.8 $2.25 6/15/2025475,300 shares $1.01 million -2.9%1.3%6.5 $2.13 5/31/2025489,400 shares $1.15 million -17.2%1.4%6.4 $2.35 5/15/2025591,000 shares $1.30 million -9.8%1.7%6.7 $2.20 4/30/2025655,100 shares $1.52 million -7.6%N/A2.9 $2.32 4/15/2025708,800 shares $1.58 million +8.9%2.0%3 $2.23 3/31/2025650,800 shares $1.39 million -2.1%1.9%2.7 $2.14 3/15/2025664,600 shares $1.59 million +7.9%1.9%2.6 $2.39 Get the Latest News and Ratings for ORMP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/28/2025616,000 shares $1.29 million +6.9%1.8%2.2 $2.09 2/15/2025576,400 shares $1.38 million +149.0%1.7%2.1 $2.40 1/31/2025231,500 shares $518.56 thousand -6.7%N/A0.9 $2.24 1/15/2025248,200 shares $580.79 thousand +2.4%N/A1.6 $2.34 12/31/2024242,300 shares $586.37 thousand -16.9%N/A1.7 $2.42 12/15/2024291,400 shares $719.76 thousand -2.7%N/A2.2 $2.47 11/30/2024299,500 shares $709.82 thousand -4.6%N/A2.4 $2.37 11/15/2024313,900 shares $700.00 thousand +4.6%N/A3.1 $2.23 10/31/2024300,000 shares $714 thousand +0.5%N/A3 $2.38 10/15/2024298,500 shares $701.48 thousand -12.3%N/A3 $2.35 9/30/2024340,400 shares $830.58 thousand -4.0%N/A3.4 $2.44 9/15/2024354,400 shares $882.46 thousand -2.4%N/A2.9 $2.49 8/31/2024363,200 shares $868.05 thousand +53.0%N/A2.7 $2.39 8/15/2024237,400 shares $557.89 thousand -14.6%N/A1.7 $2.35 7/31/2024278,100 shares $709.16 thousand -16.9%N/A2.1 $2.55 7/15/2024334,700 shares $846.79 thousand -36.7%N/A2.7 $2.53 6/30/2024529,100 shares $1.36 million +13.1%N/A4 $2.57 6/15/2024467,800 shares $1.05 million +63.3%N/A4 $2.25 5/31/2024286,500 shares $624.57 thousand -5.9%N/A2.6 $2.18 5/15/2024304,600 shares $727.99 thousand -6.2%N/A2.5 $2.39 4/30/2024324,600 shares $753.07 thousand -11.7%N/A2.2 $2.32 4/15/2024367,600 shares $889.59 thousand -37.0%N/A2.2 $2.42 3/31/2024583,900 shares $1.70 million +20.6%N/A3.3 $2.92 3/15/2024484,000 shares $1.41 million -3.3%N/A2.6 $2.92 2/29/2024500,700 shares $1.65 million -27.6%N/A2.5 $3.29 2/15/2024691,600 shares $2.17 million +76.0%N/A3.6 $3.14 1/31/2024393,000 shares $1.18 million +5.3%N/A2.1 $3.00 1/15/2024373,200 shares $873.29 thousand +17.4%N/A1.8 $2.34 12/31/2023318,000 shares $734.58 thousand -15.4%N/A1.6 $2.31 12/15/2023376,000 shares $827.20 thousand -10.0%N/A2 $2.20This stock could leave NVDA in the dust (Ad)Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.Click to get the full details on Eric Fry's "Nvidia alternative" right here. 11/30/2023417,800 shares $927.52 thousand -10.3%N/A2.4 $2.22 11/15/2023465,900 shares $959.75 thousand +3.6%N/A2.6 $2.06 10/31/2023449,800 shares $823.13 thousand -23.6%N/A2.5 $1.83 10/15/2023588,400 shares $1.28 million -2.2%N/A3.5 $2.18 9/30/2023601,800 shares $1.57 million +6.3%N/A3.4 $2.61 9/15/2023566,200 shares $1.72 million +25.8%N/A2.8 $3.04 8/31/2023450,000 shares $1.48 million -13.7%N/A1.8 $3.28 8/15/2023521,600 shares $1.63 million +4.0%N/A1.4 $3.13 7/31/2023501,400 shares $1.70 million -25.9%N/A0.6 $3.39 7/15/2023677,000 shares $2.17 million -15.1%N/A0.8 $3.21 6/30/2023797,800 shares $2.86 million -6.5%N/A0.9 $3.58 6/15/2023852,900 shares $3.45 million -7.6%N/A0.9 $4.04 5/31/2023923,300 shares $3.73 million +89.9%N/A1 $4.04 5/15/2023486,300 shares $1.52 million -6.6%N/A0.5 $3.13 4/30/2023520,400 shares $1.18 million -33.4%N/A0.7 $2.27 4/15/2023781,200 shares $1.75 million -1.0%N/A0.9 $2.24 3/31/2023789,300 shares $1.72 million -19.9%N/A0.5 $2.18 3/15/2023985,700 shares $1.99 million -7.0%N/A0.6 $2.02 2/28/20231,060,000 shares $2.23 million +8.3%N/A0.6 $2.10 2/15/2023978,500 shares $2.15 million +3.4%N/A0.6 $2.20 1/31/2023946,000 shares $1.88 million -65.6%N/A0.6 $1.99 1/15/20232,750,000 shares $6.19 million -2.5%N/A2.1 $2.25 12/30/20222,820,000 shares $33.92 million +4.8%N/A6.9 $12.03 12/15/20222,690,000 shares $22.00 million -2.2%N/A9.1 $8.18 11/30/20222,750,000 shares $23.24 million -5.5%N/A10.5 $8.45 11/15/20222,910,000 shares $26.19 million -3.6%N/A10.9 $9.00 10/31/20223,020,000 shares $21.47 million +0.7%N/A11 $7.11 10/15/20223,000,000 shares $18.72 million -3.2%N/A9.4 $6.24 9/30/20223,100,000 shares $20.09 million +4.7%N/A3.7 $6.48 9/15/20222,960,000 shares $24.92 million -0.3%N/A2.3 $8.42 8/31/20222,970,000 shares $25.42 million -0.7%N/A2.2 $8.56 8/15/20222,990,000 shares $29.63 million -6.9%N/A2.1 $9.91 7/31/20223,210,000 shares $28.18 million -10.6%N/A2.1 $8.78 7/15/20223,590,000 shares $28.65 million +30.1%N/A2.3 $7.98 6/30/20222,760,000 shares $12.64 million -25.4%N/A1.8 $4.58 6/15/20223,700,000 shares $14.65 million +12.8%30.1%4.7 $3.96 5/31/20223,280,000 shares $15.19 million +1.6%N/A5.1 $4.63 5/15/20223,230,000 shares $14.76 million +26.2%N/A5.3 $4.57 4/30/20222,560,000 shares $13.16 million +15.8%N/A4.8 $5.14 4/15/20222,210,000 shares $15.16 million -6.8%N/A3.6 $6.86 3/31/20222,370,000 shares $20.50 million +4.9%N/A3.8 $8.65 3/15/20222,260,000 shares $20.05 million +2.7%N/A3.1 $8.87 2/28/20222,200,000 shares $22.66 million -2.2%N/A2.8 $10.30 2/15/20222,250,000 shares $26.15 million +2.3%N/A2.5 $11.62 1/31/20222,200,000 shares $19.71 million +9.5%N/A2.3 $8.96 1/15/20222,010,000 shares $22.21 million -9.1%N/A2.2 $11.05 12/31/20212,210,000 shares $31.56 million +10.0%N/A2.6 $14.28 12/15/20212,010,000 shares $30.33 million +122.9%N/A2.5 $15.09 11/30/2021901,600 shares $17.33 million -3.4%N/A1.1 $19.22 11/15/2021933,400 shares $26.28 million -3.5%N/A1.2 $28.16This stock could leave NVDA in the dust (Ad)Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.Click to get the full details on Eric Fry's "Nvidia alternative" right here. 10/29/2021967,400 shares $22.65 million -7.9%N/A1.2 $23.41 10/15/20211,050,000 shares $23.16 million -3.7%3.7%1.3 $22.06 9/30/20211,090,000 shares $23.96 million -2.7%3.8%1.2 $21.98 9/15/20211,120,000 shares $21.78 million -5.9%3.9%1.3 $19.45 8/31/20211,190,000 shares $23.42 million -13.8%4.2%1.5 $19.68 8/13/20211,380,000 shares $24.40 million -27.8%4.9%1.8 $17.68 7/30/20211,910,000 shares $27.10 million -14.7%6.9%2.8 $14.19 7/15/20212,240,000 shares $28.45 million -6.3%8.1%4.1 $12.70 6/30/20212,390,000 shares $31.98 million +10.7%8.9%4.7 $13.38 6/15/20212,160,000 shares $28.84 million -12.9%8.0%4.7 $13.35 5/28/20212,480,000 shares $28.57 million -0.8%9.6%3.8 $11.52 5/14/20212,500,000 shares $25.65 million +7.3%9.7%4 $10.26 4/30/20212,330,000 shares $25.33 million +4.5%9.1%3.4 $10.87 4/15/20212,230,000 shares $20.69 million +0.5%8.7%2.6 $9.28 3/31/20212,220,000 shares $22.44 million +22.7%9.0%2.7 $10.11 3/15/20211,810,000 shares $17.01 million +4.0%7.4%2.2 $9.40 2/26/20211,740,000 shares $15.57 million -4.4%7.1%2.6 $8.95 2/12/20211,820,000 shares $18.56 million +45.6%7.6%2 $10.20 1/29/20211,250,000 shares $8.74 million +54.8%5.3%1.5 $7.00 1/15/2021807,700 shares $3.60 million No Change3.8%1.3 $4.46 ORMP Short Interest - Frequently Asked Questions What is Oramed Pharmaceuticals' current short interest? Short interest is the volume of Oramed Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of July 31st, investors have sold 403,800 shares of ORMP short. 1.20% of Oramed Pharmaceuticals' shares are currently sold short. Learn More on Oramed Pharmaceuticals' current short interest. What is a good short interest ratio for Oramed Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ORMP shares currently have a short interest ratio of 6.0. Learn More on Oramed Pharmaceuticals's short interest ratio. What is a good short interest percentage for Oramed Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.20% of Oramed Pharmaceuticals' floating shares are currently sold short. Is Oramed Pharmaceuticals' short interest increasing or decreasing? Oramed Pharmaceuticals saw a decrease in short interest in the month of July. As of July 31st, there was short interest totaling 403,800 shares, a decrease of 0.1% from the previous total of 404,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Oramed Pharmaceuticals' short interest compare to its competitors? 1.20% of Oramed Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oramed Pharmaceuticals: 4D Molecular Therapeutics, Inc. (8.84%), Inhibrx Biosciences, Inc. (6.86%), Candel Therapeutics, Inc. (17.60%), Larimar Therapeutics, Inc. (8.06%), Rocket Pharmaceuticals, Inc. (13.83%), Amarin Corporation PLC (2.31%), Aldeyra Therapeutics, Inc. (9.29%), Altimmune, Inc. (33.12%), CytomX Therapeutics, Inc. (31.82%), Canopy Growth Corporation (14.13%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Oramed Pharmaceuticals stock? Short selling ORMP is an investing strategy that aims to generate trading profit from Oramed Pharmaceuticals as its price is falling. ORMP shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Oramed Pharmaceuticals? A short squeeze for Oramed Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ORMP, which in turn drives the price of the stock up even further. How often is Oramed Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ORMP, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies 4D Molecular Therapeutics Short Interest Data Inhibrx Biosciences Short Interest Data Candel Therapeutics Short Interest Data Larimar Therapeutics Short Interest Data Rocket Pharmaceuticals Short Interest Data Amarin Short Interest Data Aldeyra Therapeutics Short Interest Data Altimmune Short Interest Data CytomX Therapeutics Short Interest Data Canopy Growth Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ORMP) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access